-
Uncategorized2 weeks agoCongo’s Ebola outbreak has killed nearly 1,000 people
BUNIA, Congo — At least 999 people have died from the Ebola outbreak in Congo, according to official data published overnight into Wednesday, a grim toll in...
-
Uncategorized2 weeks ago
NIH joins Trump’s $5B AI mission with biomedical research push
The U.S. Department of Health and Human Services announced new efforts Wednesday aligned with President Donald Trump’s artificial intelligence-driven Genesis Mission. The centerpiece of HHS’ participation...
-
Uncategorized2 weeks ago
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of...
-
Uncategorized2 weeks ago
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
-
Uncategorized2 weeks agoWhy the biggest gains in clinical R&D won’t come from technology
Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every few years, the clinical research industry rallies around...
-
Uncategorized2 weeks ago
6 companies hiring in Cambridge now
6 companies hiring in Cambridge now
-
Uncategorized2 weeks agoSTAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days...
-
Uncategorized2 weeks ago
US ‘eroding’ lead in rare diseases a matter of national security: Report
A Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the...
-
Uncategorized2 weeks ago
Engitix Licenses Lonza’s Technology to Advance ADC Therapies
Engitix Licenses Lonza’s Technology to Advance ADC Therapies
-
Uncategorized2 weeks agoCrystalys nets $130M more to push gout drug through late-stage tests
The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in...
